AZ-23

SKU: orb1741542

Description

AZ-23 is a potent ATP-competitive inhibitor targeting Trk kinases (A/B/C) and other kinases including FGFR1 and Flt3. It is a valuable research tool for investigating neurotrophic signaling pathways and kinase roles in cancer, with utility in both in vitro and in vivo experimental models.

Research Area

Signal Transduction

Key Properties

• CAS Number: 915720-21-7
• MW: 391.83
• Purity: 99.40% (May vary between batches)
• Formula: C₁₇H₁₉ClFN₇O
• SMILES: CC(C)Oc1cc(Nc2nc(N[C@@H](C)c3ccc(F)cn3)ncc2Cl)n[nH]1
• Target: Trk receptor
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (10.21 mM);DMSO:125 mg/mL (319.02 mM)

Bioactivity

• Target IC50:
  TrkB:8 nM|TrkA:2 nM
• In Vivo:
  Following oral administration in a TrkA-driven allograft model, AZ-23 demonstrates effective in vivo inhibition of TrkA kinase and efficacy in mice. It also significantly inhibits tumor growth in a Trk-expressing xenograft model of neuroblastoma.
  Read more...
• In Vitro:
  AZ-23 selectively and potently inhibits Trk phosphorylation in cells, with an EC50 of 2 nM for Trk-mediated survival. It also inhibits Trk-dependent survival in MCF10ATrkA-Δ and TF-1 cell lines.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Tropomyosin related kinase receptor, TrkA, Trk receptor, Trk Receptor, Trkreceptor, TrkB, AZ23, AZ-23, AZ 23, inhibit, Inhibitor

Compound Identifiers

PubChem CID

16097523